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This paper describes the validation of a reversed-phase high performance liquid chromatography method 
(RP-HPLC) with diode array detection (DAD) for determination of related substances (impurities from 
organic synthesis and degradation products) of captopril according to the Brazilian Pharmacopeia IV. 
The aim of this study was to guarantee the method accuracy for quantification of related substances, 
an essential requisite to determine, using the mass balance approach, the captopril content in the first 
Brazilian certified reference material (CRM) of an active pharmaceutical ingredient (API), developed by 
Inmetro. The captopril instability in solution is discussed and the captopril content determined by mass 
balance is compared to the results from titration and differential scanning calorimetry (DSC).
Uniterms: Captopril/qualitative analysis. Medicines/analysis/method validation. Medicines/analytical 
quality control. High performance liquid chromatography/qualitative analysis. Medicines/contamination. 
Captopril/certified reference standards.
Este artigo descreve a validação de método de cromatografia líquida de alta eficiência em fase reversa 
(CLAE-RP) com detector de fotodiodos (DAD) para determinação de substâncias relacionadas (impurezas 
orgânicas de síntese e produtos de degradação) de captopril segundo Farmacopéia Brasileira IV ed. 
Este estudo teve como objetivo garantir que o método é capaz de quantificar com exatidão o teor de 
substâncias relacionadas, um requisito essencial para que o teor de captopril seja determinado por 
balanço de massa no primeiro material de referência certificado (MRC) de fármacos brasileiro, o qual 
foi desenvolvido pelo Inmetro. A instabilidade do captopril em solução é discutida em detalhes e o teor 
de captopril determinado por balanço de massa é comparado com aqueles obtidos por titulação e por 
calorimetria exploratória diferencial (DSC).
Unitermos: Captopril/análise qualitativa. Medicamentos/análise/validação de método. Medicamentos/
controle analítico de qualidade. Cromatografia líquida de alta eficiência/análise qualitativa. Medicamentos/
contaminação. Captopril/padrões de referência.
INTRODUCTION
The Brazilian National Institute of Metrology, Stan-
dardization and Industrial Quality (Inmetro) has recently 
started a project to develop certified reference materials 
(CRMs) of active pharmaceutical ingredients (APIs). 
In 2010, the captopril CRM, which is the first Brazilian 
certified reference material of API, was presented by this 
institute. Captopril is an angiotensin I converting enzyme 
inhibitor widely used in the treatment of hypertension and 
congestive heart failure (Stultzer at al., 2009).
CRMs are defined as stable and homogeneous mate-
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rials, which are accompanied by a certificate declaring the 
value of a specified property (the API content in the scope 
of this paper) and the associated measurement uncertain-
ty, in order to guarantee metrological traceability (ISO 
Guide 35:2006; JCGM, 2008). This traceability, which is 
a requirement of the ISO 17025:2005 standard and corres-
ponds to “an unbroken chain of comparisons to national 
or international standards, all having stated uncertainties” 
(Duewer et al., 2004), cannot be ensured through the use 
of “non-certified” reference materials (also called reference 
standards).
The availability of certified reference materials for 
pharmaceutical use remains limited. The United States 
Pharmacopeia (USP), for instance, whose reference stan-
dards have been available since 1926 (Williams et al., 
2006), developed its first CRM only in September 2008: 
dextromethorphan hydrobromide, which was followed 
in 2009 by theophylline, phenytoin and carbamazepine 
CRMs (The United States Pharm. Convention, 2010). We 
expect that in the near future the demand for pharmaceuti-
cal CRMs may be increasingly met by Pharmacopeias or 
National Metrology Institutes (NMIs).
The requirements for preparation of CRMs are 
described by the ISO Guides 34:2009 and 35:2006, and 
include material characterization, homogeneity evalu-
ation, short- and long-term stability studies, as well as 
measurement uncertainty estimation.
The characterization step includes the determination 
of the property value, which in our case was the captopril 
content in the CRM and was determined by mass balance 
according to eq. 1.
Captopril (%) = 100 % – Σ organic impurities (%) – 
Σ inorganic impurities (%) – Σ volatiles (water and sol-
vents) (%) (eq. 1)
The mass balance approach allows determination of 
API content with standard deviations up to 10 times lower 
than those obtained by traditional assay methods (Hofer, 
Olsen, Rickard, 2007). The precision of the HPLC assays, 
for instance, is estimated to be in the range of 0.5-1.0% 
(Gorog, 2005). More precise results (smaller standard 
deviations) have the advantage of consequently lower 
associated measurement uncertainties. This justifies the 
increasing importance of tests for determination of impuri-
ties compared to those for assay of analytes (Gorog, 2005).
In order to use the mass balance equation, it is ne-
cessary to accurately quantify all impurities, including 
those from organic synthesis and degradation products. 
The organic impurities content in the captopril candidate 
certified reference material was determined by RP-HPLC-
DAD, according to the related substances test method 
given in the Brazilian Pharmacopeia IV monograph in 
question. This method has been validated, as described in 
this article, in order to guarantee that it is adequate for the 
intended use (ICH, 1994; Anvisa, 2003; ISO 17025:2005) 
and to prove its capacity to generate accurate results that 
could be used for the mass balance calculation.
MATERIALS AND METHODS
Instrumentation
For determination of related substances, a high perfor-
mance liquid chromatographic (HPLC) Shimadzu system 
equipped with a quaternary pump LC-20AT, on-line degas-
ser DGU-20A3/DGU-20A5, auto-sampler SIL-20A/20AC, 
photodiode array detector SPD-20A and interface CBM-
20A/20A, was used. The data were processed using the 
software Lab Solution. The system suitability test (5 repli-
cate injections, allowed relative standard deviation for peak 
areas < 2 %) (USP 32) was carried out before each set of 
validation experiments using a 10 µg/g captopril solution, 
in order to confirm the HPLC system performance.
The differential scanning calorimetry measurements 
were performed using a DSC Q1000 (TA Instruments) 
according to Moreira et al. (2010). For gravimetric pre-
paration of samples, an analytical balance AUW 220D 
(Shimadzu) with 0.01 mg resolution was used.
Samples and reagents
The studies were performed using samples of the 
first Inmetro batch of captopril CRM, whose certified 
reference value and expanded uncertainty (U), using the 
value of 2 as coverage factor for a confidence level of ap-
proximately 95 % (ABNT / Inmetro, 2003), was 99.565 + 
0.093 % w/w (Nogueira et al., in press).
The captopril USP reference standard (batch H 
09120H, 100.0 %) and the captopril disulfide USP reference 
standard (batch H0F251, 99.0 %) were not dried before use.
The reagents used for sample preparation and chro-
matographic analysis were methanol HPLC grade (Tedia 
Brazil), o-phosphoric acid 85 % w/w for analysis (Tedia 
Brazil), hydrochloric acid p.a. (Merck), sodium hydroxide 
p.a. (Merck), hydrogen peroxide 30 % p.a. (Merck) and 
water type I.
Method description
The HPLC method was based on the related subs-
tances test of captopril described in the corresponding 
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Brazilian Pharmacopeia IV monograph. The analysis 
conditions were: mobile phase, methanol - phosphoric acid 
0.11 % (55:45, v/v); flow-rate, 1 ml/min; UV detection, 
220 nm; injection volume, 20 µl. The HPLC column was 
RP18, 25 cm x 4.6 mm i.d., 5 µm, Supelcosil (Supelco), 
to which a pre-column RP18, 4.6 mm i.d., 5 µm (Varian) 
was attached.
Method validation
All solutions for validation studies were prepared 
gravimetrically, using mobile phase as the diluent.
The method specificity was evaluated by means 
of analysis of diluent (mobile phase), captopril disulfide 
USP reference standard (10 µg/g solution), captopril USP 
reference standard (500 and 10 µg/g solutions), captopril 
CRM samples (500 and 10 µg/g solutions), mixtures of 
captopril disulfide USP reference standard and captopril 
CRM (solutions containing 10 and 500 µg/g, respectively) 
and mixtures of captopril disulfide and captopril USP re-
ference standards (solutions containing 10 and 500 µg/g, 
respectively). Additionally, samples of captopril CRM 
exposed to temperatures of 80 °C, 120 °C, 140 °C and 
250 °C or treated with 1 mol/L HCl, 1 mol/L NaOH or 3% 
H2O2 for 5 h were analyzed. After treatment, the samples 
were neutralized (in case of acidic or basic conditions) 
and then diluted with mobile phase to reach the analysis 
concentrations (500 and 10 µg/g solutions).
In order to evaluate the captopril stability in the di-
luent (mobile phase), 500 µg/g solutions of captopril CRM 
(prepared in triplicate from flasks 16, 180 and 446) were 
transferred to HPLC vials and kept at 15 °C in the auto-
sampler. The first injection of all solutions was performed 
in a random fashion, being followed by injections 2 and 
3 performed in the same manner. The test was repeated 
using freshly prepared CRM solutions.
The linearity test was carried out using 11 individual 
solutions of captopril and captopril disulfide USP referen-
ce standards in the concentration range of 0.01 to 500 µg/g. 
The captopril solutions were prepared both from the same 
stock solution and from different stock solutions freshly 
made before injection. For captopril disulfide, the dilutions 
were prepared from the same stock solution.
The limit of detection (LOD) and the limit of quan-
titation (LOQ) were initially estimated from the linearity 
data. For captopril disulfide, the results were then con-
firmed by preparing a dilution series (9 solutions) in the 
concentration range of 0.01 µg/g to 1.00 µg/g, which was 
sufficient to obtain responses (peak heights) equivalent to 
around 10 times the noise (estimated from baseline) (LOQ) 
or to around 3 times the noise (LOD), as required by the 
signal-to-noise (S/N) ratio method (ICH, 1994).
The repeatability was evaluated by six repeated in-
jections of captopril and captopril disulfide USP reference 
standards (10 µg/g individual solutions). This test was 
repeated on a different day by a different analyst in order 
to verify intermediate precision.
The recovery tests for accuracy evaluation were 
performed using solutions of captopril disulfide USP 
reference standard at the concentrations of 7.5, 10.0 and 
12.5 µg/g (75% to 125% of the total organic impurity li-
mit of 10 µg/g), with or without the addition of 500 µg/g 
of captopril CRM or captopril USP reference standard 
(considered as matrixes). These two matrixes were also 
individually analyzed to determine their original captopril 
disulfide content.
For comparison of different methods, the mass ba-
lance calculation of the captopril content was done using 
eq. 1. The content of organic impurities in the captopril 
CRM was determined by RP-HPLC-DAD, the inorganic 
impurities were estimated by residue of ignition (sulphated 
ash) using 9 captopril CRM samples of 1 g each, ignited at 
600 °C until constant weight after addition of sulfuric acid, 
while the volatiles were determined by loss on drying at 
60 °C under vacuum for 3 hours using 10 captopril CRM 
samples of 0.5 g each.
The robustness test was done by HPLC analysis of 
diluent (mobile phase), captopril CRM solution (10 µg/g) 
and captopril USP reference standard solution (10 µg/g) 
analyzed under eight different experimental conditions, 
which will be described in the corresponding section.
RESULTS AND DISCUSSION
The following parameters were evaluated for the 
method validation:
1. Specificity;
2. Stability of solutions;
3. Linearity and working range;
4. Limit of detection (LOD) and limit of quantitation 
(LOQ);
5. Repeatability and intermediate precision; 
6. Accuracy;
7. Robustness.
Specificity
According to resolution RE-899 of the Brazilian 
National Health Surveillance Agency (Anvisa, 2003), spe-
cificity is the capacity of the method to measure exactly the 
compound of interest, even in the presence of impurities, 
degradation products and matrix components. 
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Figures 1 and 2 show the chromatograms for cap-
topril disulfide and captopril USP reference standards, 
respectively, while Figure 3 shows the chromatogram for 
the captopril CRM. Captopril eluted at the retention time 
tR = 4.3 min, while its main impurity captopril disulfide 
eluted at the retention time tR = 6.7 min. Captopril disulfide 
was present as an impurity both in the captopril USP refe-
rence standard (content around 0.07 %) (Figure 2) and in 
the captopril CRM (Figure 3). For captopril CRM samples, 
FIGURE 1 - Chromatogram of captopril disulfide USP reference 
standard (10 µg/g), showing captopril disulfide peak (tR = 6.7 min) 
and mobile phase signals. Experimental conditions: HPLC 
column, RP18 25 cm x 4.6 mm i.d. 5 µm; mobile phase, methanol 
- phosphoric acid 0.11% (55:45, v/v); flow-rate, 1 mL/min; UV 
detection, 220 nm; injection volume, 20 µL.
FIGURE 2 - Chromatogram of captopril USP reference standard (500 µg/g) (a) in full scale and (b) in enlarged view, showing peaks 
of captopril (tR = 4.3 min) and its main impurity captopril disulfide (tR = 6.7 min) present in small amount, as well as mobile phase 
signals. Experimental conditions: see Figure 1.
the chromatograms showed, besides the peaks of captopril 
and captopril disulfide, three peaks of unknown impurities 
(tR = 3.5 min, tR = 3.7 min and tR = 6.0 min) (Figure 3).
The diluent (mobile phase) was responsible for two 
signals observed in the chromatograms, whose areas re-
mained constant during the validation and RM certification 
experiments, and which were sufficiently resolved from 
the peaks of captopril and captopril disulfide (Figures 1 to 
3). There was no indication that these signals could overlap 
with an impurity peak based on the specificity test results: 
no increase in the areas of these diluent peaks was obser-
ved in the chromatograms of samples exposed to intense 
stress conditions (80 °C, 120 °C, 140 °C, 250 °C, 1 mol/L 
HCl, 1 mol/L NaOH and 3% H2O2).
The results for the specificity test are summarized 
in Table I. The peaks of captopril and captopril disulfide 
were sufficiently resolved (Rs 5.0), in accordance with the 
Brazilian Pharmacopeia IV acceptance criteria (Rs min 
2.0). For the peaks of captopril and captopril disulfide, 
peak purity indexes of at least 0.98 were obtained, even 
after exposure of samples to temperatures up to 140 ºC or 
to other stress conditions (acidic, basic or oxidizing). The 
disulfide captopril could be sufficiently recovered in the 
presence of matrixes (captopril USP reference standard or 
captopril CRM) (at least 96.8 %). Therefore, the method 
validation regarding specificity has been demonstrated.
Stability of solutions
Of the nine captopril impurities described in the 
literature (LGC, 2010), captopril disulfide was the main 
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FIGURE 3 - Chromatogram of captopril candidate CRM (500 µg/g) (a) in full scale and (b) in enlarged view, showing the peaks 
of captopril (tR = 4.3 min), captopril disulfide (tR = 6.7 min), three unknown impurities (tR = 3.5 min, tR = 3.7 min and tR = 6.0 min) 
and mobile phase signals. Experimental conditions: see Figure 1.
TABLE I - Specificity tests using captopril and captopril disulfide solutions, with evaluation of peak purity indexes, peak resolution, 
recoveries and behavior under stress conditions
Captopril disulfide Captopril Resolution
tR 
(min)
Assay 
(%) 
Peak 
purity 
index
tR 
(min)
Assay 
(%)
Peak 
purity 
index
C/I (4) C/D (5)
Diluent - - - - - - - -
Disulfide std (1) 10 µg/g 6.52 99.0 (3) 1.000 - - - - -
Captopril std (2) 500 µg/g 6.50 0.07 - 4.21 100.0 (3) 1.000 - 5.18
Captopril std 10 µg/g - - - 4.21 100.0 (3) 1.000 - -
Captopril CRM 500 µg/g 6.49 0.23 - 4.21 98.93 1.000 1.34 5.01
Disulfide std + captopril CRM (10 + 500 µg/g) 6.52 96.82 1.000 4.21 - 1.000 - -
Disulfide std + captopril std (10 + 500 µg/g) 6.48 97.65 1.000 4.21 - 1.000 - -
Captopril CRM under stress conditions: 
80 °C - - 1.000 - - 0.980 - -
120 °C - - 0.982 - - 0.980 - -
140 °C - - 0.989 - - 0.987 - -
250 °C - - 0.927 - - 0.955 - -
1 mol/L HCl - 0.82 1.000 - 97.84 1.000 - -
1 mol/L NaOH - 0.44 1.000 - 97.27 1.000 - -
3% H2O2 - 2.67 1.000 - 88.42 1.000 - -
(1) Captopril disulfide USP reference standard 
(2) Captopril USP reference standard 
(3) According to USP reference standards certificate
(4) Resolution between the peaks of captopril and the closest impurity (tR = 3.7 min)
(5) Resolution between the peaks of captopril and disulfide
impurity. When captopril (Figure 4a) is dissolved in water, 
it oxidizes spontaneously at its sulfhydryl group, forming 
the disulfide (Figure 4b) (Nishikawa et al., 2004). Addi-
tionally, the captopril molecule has an amide function and 
can undergo hydrolysis (Timmins, Jackson, Wang, 1982). 
The stability of solutions prepared for impurity analysis 
was therefore a critical parameter to be evaluated.
Captopril CRM solutions, prepared from three 
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different flasks in triplicate, were analyzed in such a way 
that the intervals between two sequential injections of the 
same solution (1/2 and 2/3) were, on average, 5 hours. The 
captopril percent peak area reduced significantly between 
the first and the third injections of each analyzed solution 
(Figure 5a), showing an increase in the percent peak areas 
of captopril disulfide (Figure 5b) and of unknown impu-
rities (Figure 5c).
Since the related substances test for captopril des-
cribed in the Brazilian Pharmacopeia IV monograph is 
a limit test (maximum of 1% captopril disulfide and 2% 
total impurities), even if increasing amounts of disulfide 
and unknown impurities are formed, the raw material can 
still comply with this acceptance criteria. However, the 
characterization of the captopril CRM required an accurate 
determination of the organic impurities content, allowing 
the use of this result for the calculation of the captopril 
content by mass balance (eq. 1). Additionally, changes 
in peak areas are also a problem for method validation, 
especially for repeatability.
Therefore, the validation tests were performed using 
fresh solutions of captopril, prepared immediately before 
injection. This procedure significantly reduced captopril 
degradation as well as the corresponding formation of 
captopril disulfide and unknown impurities in solution. 
Linearity and working range
Linearity is the ability of the analytical method to 
produce results directly proportional to the analyte con-
centration within a defined range (Inmetro, 2007). 
Considering the instability of captopril in solution, 
the linearity tests were performed using: a) dilutions 
prepared from the same stock solution (higher risk of de-
gradation) and; b) solutions prepared from different stock 
solutions, immediately prior to injection. Since no degra-
dation was observed for the disulfide reference standard, 
its dilutions were prepared from the same stock solution.
The linearity for captopril and captopril disulfide 
was initially evaluated in the concentration range of 0.01 to 
500 µg/g. After determination of the limits of quantitation 
(LOQ), as described in the next section, the results below 
LOQ were disregarded. Additionally, the linearity was also 
evaluated in a narrower range between LOQ and 50 µg/g, 
which corresponds to the most appropriate concentration 
range for organic impurities in CRM samples (the limits of 
captopril disulfide and total impurities in captopril samples 
are 1% and 2%, respectively, according to the Brazilian 
Pharmacopeia IV, which correspond to 5 µg/g and 10 µg/g 
for solutions containing 500 µg/g of captopril).
FIGURE 4 - Structural formulas of captopril (a) and of its main 
impurity, captopril disulfide (b).
FIGURE 5 – Percent peak areas of captopril (a), captopril 
disulfide (b) and unknown impurities (c) for solutions containing 
500 µg/g of captopril CRM (3 samples, solutions prepared in 
triplicate), which were prepared in the same set, kept at 15 °C 
in the auto-sampler and injected into the HPLC system, with 
5-hour intervals between injections.
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The statistics of the calibration curves are shown 
in Table II. All correlation coefficients complied with the 
acceptance criteria (r > 0.99 according to Ribani et al. 
(2004), equivalent to r2 > 0.98). Therefore, the linearity 
has been demonstrated.
Limit of detection (LOD) and limit of quantitation 
(LOQ)
The limit of detection (LOD) is the lowest analyte 
concentration that can be detected, but cannot be exactly 
quantified, while the limit of quantitation (LOQ) is the 
lowest analyte concentration that can be quantified with 
precision and accuracy (ICH, 1994).
The values of LOD and LOQ of captopril and capto-
TABLE II - Linearity evaluation for captopril disulfide and captopril in two different concentration ranges (LOQ to 50 µg/g and 
LOQ to 500 µg/g)
Captopril disulfide Captopril (same stock solution)
Captopril (different stock 
solutions prepared before 
injection)
Concentration range LOQ-500 µg/g LOQ-50 µg/g LOQ-500 µg/g LOQ-50 µg/g LOQ-500 µg/g LOQ-50 µg/g
Intercept (1) 7666.82 -3068.42 12075.10 1320.53 484.39 -1851.37
Slope (2) 13122.98 13368.82 10472.04 10707.37 11671.12 11656.76
r2 (3) 0.999964 0.999763 0.999934 0.999995 0.999893 0.999278
n (4) 27 18 27 18 27 18
(1) Intercept “a” of the linear regression analysis curve y = bx + a
(2) Slope “b” of the linear regression analysis curve y = bx + a
(3) Squared correlation coefficient
(4) Number of measurements
TABLE III - Determination of limit of quantitation (LOQ) and limit of detection (LOD) for captopril disulfide and captopril
Captopril disulfide
Captopril (same stock 
solution)
Captopril (different stock 
solutions prepared before 
injection)
LOQ (µg/g) LOD (µg/g) LOQ (µg/g) LOD (µg/g) LOQ (µg/g) LOD (µg/g)
Estimation from linearity data 0.3277 0.0983 0.2259 0.0678 0.2535 0.0760
Dilution series (1.00 - 0.01 µg/g)
Average - day 1 0.3461 0.1038
Average - day 2 0.3406 0.1022 - - - -
Average - day 3 0.3736 0.1121
Average days 1-3 0.3534 0.1060
SD (1) 0.0177 0.0053 - - - -
CV (%) (2) 5.01 5.01
(1) Standard deviation
(2) Coefficient of variation
pril disulfide were first calculated from the linearity data. 
The estimated values for captopril disulfide were then 
confirmed by repetition of the experiments using a larger 
number of samples in the concentration range of 0.01 to 
1.00 µg/g and the limits were determined according to the 
signal-to-noise ratio method (ICH, 2004).
The following values of LOQ and LOD were ob-
tained: 0.35 µg/g and 0.11 µg/g for captopril disulfide; 
0.25 µg/g and 0.08 µg/g for captopril, respectively (Table 
III). The LOQ of captopril can be used as a reference 
value for unknown impurities. These results were con-
sidered satisfactory, since these values are at least ten 
times lower than the captopril disulfide limit in captopril 
samples (1% or 5 µg/g disulfide for 500 µg/g captopril 
solutions). 
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Repeatability and intermediate precision
Repeatability is the degree of compliance between 
the results of successive measurements under the same 
analysis conditions (same procedure, analyst and equip-
ment, analysis in a short time frame), while the reprodu-
cibility evaluates the compliance between measurements 
under different analysis conditions (different analysts, 
equipment or laboratories) (Inmetro, 2007).
This reproducibility concept can be evaluated on 
two levels:
1. Intermediate precision: compliance between 
results from the same laboratory, albeit on different days 
and by different analysts (Anvisa, 2003).
2. Reproducibility: agreement between results from 
different laboratories, usually by means of interlaboratory 
studies (Anvisa, 2003), which is beyond the scope of this 
article. 
Results for repeatability and intermediate precision 
are shown in Table IV. Repeatability was demonstrated by 
the small coefficients of variation (CV) of normalized peak 
areas and recoveries for six repeated injections of captopril 
and captopril disulfide USP reference standard solutions 
(CV: 0.41-0.44% for captopril disulfide, 0.13-0.20% 
for captopril). Intermediate precision was confirmed by 
single-factor analysis of variance (ANOVA) (Table V) 
using the recoveries from Table IV (results for two diffe-
rent days, carried out by different analysts). The calculated 
F values were smaller than the critical F values and the 
acceptance criteria were therefore fulfilled.
Accuracy
Accuracy is the agreement between the result ob-
tained and the reference value accepted as the true value. 
The accuracy evaluation can be performed by recovery 
tests, interlaboratory studies, use of reference materials 
(Inmetro, 2007) and comparison of results from different 
methods.
Recovery tests
The recovery studies were carried out using so-
lutions of captopril disulfide USP reference standard at 
concentrations of 7.5, 10.0 and 12.5 µg/g (75% to 125% 
of the total organic impurity limit of 10 µg/g), having 
500 µg/g of captopril CRM or captopril USP reference 
standard (considered as matrixes) added or otherwise. 
Since these matrixes also contained small amounts of 
TABLE IV - Repeatability and intermediate precision results for six replicate HPLC injections of captopril disulfide and captopril 
on two different days
Day-
injection
Captopril disulfide Captopril
Theoretical 
conc. 
(µg/g)
Area
Normalized 
peak area 
(10 µg/g)
Real 
conc. 
(µg/g)
Recovery 
(%)
Theoretical 
conc. 
(µg/g)
Area
Normalized 
peak area 
(10 µg/g)
Real 
conc. 
(µg/g)
Recovery 
(%)
1_1 10.97 143817 131089.21 10.55 96.19 10.28 125932 122452.18 10.76 104.59
1_2 10.97 143278 130597.91 10.51 95.81 10.28 126126 122640.82 10.77 104.75
1_3 10.97 142762 130127.58 10.47 95.45 10.28 125880 122401.61 10.75 104.55
1_4 10.97 142868 130224.20 10.48 95.52 10.28 125444 121977.66 10.71 104.19
1_5 10.97 142616 129994.50 10.46 95.35 10.28 125680 122207.14 10.73 104.38
1_6 1097 144068 131318.00 10.57 96.37 10.28 126053 122569.83 10.77 104.69
Average   130558.56  95.78   122374.87  104.53
CV % (1)   0.42  0.44   0.20  0.20
2_1 10.68 139523 130592.44 10.22 95.68 10.98 134529 122541.59 11.49 104.69
2_2 10.68 138921 130028.97 10.18 95.25 10.98 134376 122402.22 11.48 104.57
2_3 10.68 140125 131155.91 10.27 96.12 10.98 134220 122260.12 11.47 104.45
2_4 10.68 139315 130397.75 10.21 95.53 10.98 134628 122631.77 11.50 104.77
2_5 10.68 139047 130146.91 10.19 95.34 10.98 134682 122680.95 11.51 104.81
2_6 10.68 140326 131344.04 10.28 96.26 10.98 134430 122451.41 11.48 104.61
Average   130611.00  95.70   122494.68  104.65
CV % (1)   0.41  0.43   0.13  0.13
(1) Coefficient of variation
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captopril disulfide, they were individually analyzed, so 
that their captopril disulfide peak areas could be subtracted 
before recovery calculation.
The results obtained can be seen in Table VI. The 
recovery of captopril disulfide in the absence of matrixes 
was in the 93.1% to 97.4% range, while its recovery 
in the presence of matrixes was between 94.0% and 
98.6%. These two ranges are comparable and both com-
ply with the established acceptance criteria (recoveries 
between 90.0 and 110.0%), thus confirming the method 
accuracy. 
Comparison between different methods
The use of different analytical methods is recom-
mended to determine the purity of reference materials, in 
order to obtain metrologically accepted results (Duewer 
et al., 2004). For characterization of a candidate certified 
reference material in a single laboratory, two possible ap-
proaches are presented by the ISO Guide 35:2006: 1) use 
of one primary method, which is a method that does not 
rely on the use of a “measurement standard for a quantity 
of the same kind” (JCGM, 2008), and; 2) combination of 
two independent secondary methods. The other procedu-
res described by the cited ISO Guide require a network of 
laboratories.
The captopril contents determined by the following 
methods have been compared: 
1. Assay of captopril by oxidation-reduction titration 
(iodometry) according to the assay method in the 
Brazilian Pharmacopeia IV monograph;
2. Differential scanning calorimetry (DSC) according 
to Moreira et al. (2010). This thermal method deter-
mines the “degree of deviation from the expected 
behavior of an ideal 100% pure sample caused by 
the presence of impurities that are more soluble in 
the material’s liquid phase than in its solid phase” 
(Duewer et al., 2004);
3. Mass balance according to eq. 1, after determination 
of impurities by RP-HPLC-DAD (organic impuri-
ties), residue on ignition (inorganic impurities) and 
loss on drying (volatiles). 
As can be seen in Table VII, the titration results for 
the captopril CRM were greater than 100% (100.04%, 
CV 0.32%, n = 24, analysis in triplicate) and therefore 
this technique, which is a primary method (Duewer et al., 
2004; Gorog, 2005), was not indicated for characterization 
and certification of the captopril reference material. These 
results may be explained by the variability of titrimetric 
methods (Rodomonte, Montinaro, Bartolomei, 2006) 
and also by the non-specificity of this technique (Gorog, 
2005), since organic impurities usually contain a moiety 
of similar reactivity to that of the analyte (Duewer et al., 
2004; Gorog, 2005).
The DSC can also be considered a primary method, 
even if in practice empirical corrections may be necessa-
ry (Duewer et al., 2004). The captopril analysis by DSC 
demonstrated that the purity of analytes with a known im-
purity profile, such as captopril CRM, can be determined 
equivalently by DSC and HPLC (Moreira et al., 2010). The 
captopril content by DSC was 99.65 ± 0.023% mol/mol, 
while the result obtained by mass balance was 99.565 ± 
0.093% w/w (Table VII), thus indicating the accuracy of 
both methods.
Robustness
A method is considered robust when it is virtually 
insensitive to small variations (Inmetro, 2007). The ro-
TABLE V - Single-factor analysis of variance (ANOVA) of recoveries (Table IV) for intermediate precision evaluation
Source of 
variation
Captopril disulfide Captopril
SS(1) df(2) MS(3) F(4) p-value(5) Fcrit
(6) SS df MS F p-value Fcrit
Between 
groups
0.0207 1 0.0207 0.1203 0.7359 4.9646 0.0455 1 0.0455 1.4668 0.2537 4.9646
Within 
groups
1.7199 10 0.1720 0.3101 10 0.0310
Total 1.7405 11 0.3556 11
(1) Sum of squares
(2) Degrees of freedom
(3) Mean square, estimated by the equation MS = SS/df
(4) Calculated F value according to the equation F = MSbetween/MSwithin
(5) If p-value > 0.05 (and F < Fcrit) , there is no significant difference between the two data groups
(6) Critical value from the F distribution, estimated by the equation Fcrit =INVF(0.05;1;df(residual))
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TABLE VI - Recoveries of captopril disulfide in the presence of captopril matrixes for accuracy evaluation
Theoretical 
disulfide 
conc. (µg/g)
Disulfide 
peak area
Added 
matrix (µg/g)
Disulfide 
peak area in 
matrix
Corrected 
disulfide 
peak area (1)
Real 
disulfide 
conc. (µg/g)
Recovery 
(%)
Captopril disulfide USP 
reference standard
8.10 104587 - - 104587 7.54 93.09
8.10 104562 - - 104562 7.54 93.07
8.10 105421 - - 105421 7.60 93.89
11.13 145828 - - 145828 10.71 96.19
11.13 145806 - - 145806 10.71 96.17
11.13 145921 - - 145921 10.71 96.25
13.95 183387 - - 183387 13.60 97.45
13.95 182810 - - 182810 13.55 97.13
13.95 182650 - - 182650 13.54 97.04
Captopril disulfide USP 
reference standard plus 
captopril CRM
8.33 125845 575.93 17456 108389 7.83 93.95
8.33 126115 575.93 17456 108659 7.85 94.20
8.33 126738 575.93 17456 109282 7.90 94.77
11.09 162479 548.81 16634 145845 10.71 96.59
11.09 162787 548.81 16634 146153 10.73 96.80
11.09 163172 548.81 16634 146538 10.76 97.07
13.90 199924 533.54 16171 183753 13.62 98.03
13.90 199682 533.54 16171 183511 13.60 97.90
13.90 201035 533.54 16171 184864 13.71 98.64
Disulfide USP reference 
standard plus captopril USP 
reference standard
11.16 152788 562.19 5168 147620 10.85 97.20
11.16 153364 562.19 5168 148196 10.89 97.59
11.16 154194 562.19 5168 149026 10.95 98.17
(1) Disulfide peak area after subtraction of disulfide peak area in the matrix
TABLE VII - Comparison of captopril contents determined by different methods for accuracy evaluation
Mass balance (1) Titration DSC
99.565 % + 0.093 % (2) 100.04 % + 0.32 % (3) 99.650 % + 0.023 % mol/mol (3)
(1) According to eq. 1, using the following methods: RP-HPLC-DAD (organic impurities), residue on ignition (inorganic impurities) 
and loss on drying (volatiles). (2) Expanded measurement uncertainty (U). (3) Standard deviation
bustness test was planned according to Youden & Steiner 
(Inmetro, 2007) and the parameters evaluated were:
·	 Mobile phase flow-rate (1 mL/min): “A” (1.1 ml/
min), “a” (0.9 mL/min);
·	 Detection wavelength (220 nm): “B” (225 nm), “b” 
(215 nm);
·	 o-Phosphoric acid concentration in the aqueous 
phase (mobile phase) (0.11% v/v): “C” (0.12% v/v), 
“c” (0.10% v/v);
·	 Methanol concentration in the organic phase (mobile 
phase) (55% v/v): “D” (58% v/v), “d” (52% v/v).
The captopril contents in the tested CRM solutions 
(10 µg/g) (s, t, u, v, w, x, y, z) under eight different expe-
rimental conditions are shown in Table VIII. 
The factors A, a, B, b, C, c, D and d were calculated 
by equations 2 to 9 (Inmetro, 2007).
 A = (s + t + u + v) / 4  (eq. 2)
 B = (s + t + w + x) / 4  (eq. 3)
 C = (s + u + w + y) / 4  (eq. 4)
 D = (s + t + y + z) / 4  (eq. 5)
 a = (w + x + y + z) / 4  (eq. 6)
 b = (u + v + y + z) / 4  (eq. 7)
 c = (t + v + x + z) / 4  (eq. 8)
 d = (u + v + w + x) / 4  (eq. 9)
The results obtained are shown in Table IX and com-
plied with the acceptance criteria (coefficient of variation 
of all results less than 5%; differences between A and a, B 
and b, and so on, no greater than 3%). Therefore, the me-
thod was considered robust for the evaluated parameters 
(detection wavelength, mobile phase flow-rate and mobile 
phase composition).
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CONCLUSIONS
The results obtained in this study complied with the 
proposed acceptance criteria, and the RP-HPLC-DAD me-
thod for determination of related substances of captopril 
was considered validated and accurate for quantification 
of organic impurities, allowing the use of the mass balance 
approach for calculation of the captopril content in the 
captopril candidate CRM.
The observed instability of captopril in solution 
was resolved by using fresh captopril solutions, prepared 
immediately before injection into the HPLC system. 
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TABLE VIII - Captopril contents (s to z) determined under eight different experimental conditions for method robustness evaluation
1 2 3 4 5 6 7 8
A / a 1.1 mL/min 1.1 mL/min 1.1 mL/min 1.1 mL/min 0.9 mL/min 0.9 mL/min 0.9 mL/min 0.9 mL/min
B / b 225 nm 225 nm 215 nm 215 nm 225 nm 225 nm 215 nm 215 nm
C / c 0.12 % H3PO4 0.10 % H3PO4 0.12 % H3PO4 0.10 % H3PO4 0.12 % H3PO4 0.10 % H3PO4 0.12 % H3PO4 0.10 % H3PO4
D / d 58 % MeOH 58 % MeOH 52 % MeOH 52 % MeOH 52 % MeOH 52 % MeOH 58 % MeOH 58 % MeOH
Captopril 
content
99.76 % 104.08 % 106.56 % 98.74 % 106.79 % 98.42 % 99.97 % 104.53 %
s t u v w x y z
TABLE IX - Youden and Steiner parameters for method 
robustness
Captopril contents (1) Differences Robustness
A (%) a (%) A – a (%) Robust
102.28 102.43 -0.15
B (%) b (%) B – b (%) Robust
102.26 102.45 -0.19
C (%) c (%) C – c (%) Robust
103.27 101.44 1.83
D (%) d (%) D – d (%) Robust
102.09 102.63 -0.54
Average (%) 102.36
SD (2) 0.51
CV (%) (3) 0.50
(1) According to eq. 2 to eq. 9
(2) Standard deviation
(3) Coefficient of variation
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